NCT00418951View on ClinicalTrials.gov

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Voriconazole

400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily

DRUG

Liposomal amphotericin B

3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes

DRUG

Liposomal amphotericin B

9 mg/kg intravenously once per week over 2 hours +/- 15 minutes

Trial Locations (1)

77030

The University of Texas M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00418951 - Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections | Biotech Hunter | Biotech Hunter